{"abstract":"This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in: Intellectual Property: U.S. Provisional Patent Application 61/ 654,232 entitled \"High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof\" [HHS Ref. E-136-2012/0-US-01]; PCT Patent Application PCT/US2013/043633 entitled \"High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof\" [HHS Ref. E-136-2012/0-PCT-02]; Chinese Patent Application 201380039993.7 entitled \"High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof\" [HHS Ref. E-136-2012/0-CN- 03]; Japanese Patent Application 2015-515243 entitled \"High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof\" [HHS Ref. E-136- 2012/0-JP-04]; South Korea Patent Application 10-2014-7037046 entitled \"High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof\" [HHS Ref. E-136-2012/0-KR-05]; Singapore Patent Application 11201407972R entitled \"High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof\" [HHS Ref. E-136-2012/0-SG-06]; United States Patent Application 14/403,896 entitled \"High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof\" [HHS Ref. E-136- 2012/0-US-07]; and all continuing U.S. and foreign patents/patent applications for the technology family, to Lentigen Technology, Inc. The patent rights to these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective exclusive licensed territory may be the United States, Australia, Canada, the European Union, Russia, China, Hong Kong, Japan, Taiwan, South Korea and Singapore, and the field of use may be limited to: \"The development of a glypican-3 (GPC3) chimeric antigen receptor (CAR)-based immunotherapy using autologous (meaning one individual is both the donor and the recipient) primary human lymphocytes (T cells or NK cells) transfected with a lentiviral or retroviral vector, wherein the vector expresses a CAR having (1) a single antigen specificity and (2) comprising at least: (a) the complementary determining region (CDR) sequences of the anti-GPC3 antibody known as HN3; and (b) a T cell signaling domain; for the prophylaxis and treatment of GPC3-expressing cancers.\"","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/05/18/2016-11659.html","cfr_references":[],"citation":"81 FR 31246","comment_url":null,"comments_close_on":"2016-06-02","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before June 2, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-11659","effective_on":null,"end_page":31247,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/05/18/2016-11659.xml","html_url":"https://www.federalregister.gov/documents/2016/05/18/2016-11659/prospective-grant-of-an-exclusive-license-the-development-of-an-anti-gpc3-chimeric-antigen-receptor","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-11659?publication_date=2016-05-18","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-05-18/2016-11659/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":328,"last_updated":"2026-07-25 18:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-05-18/pdf/2016-11659.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-11659.pdf?1463489148","publication_date":"2016-05-18","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/05/18/2016-11659.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T08:56:15Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":31246,"subtype":null,"title":"Prospective Grant of an Exclusive License: The Development of an Anti-GPC3 Chimeric Antigen Receptor (CAR) Based on HN3 for the Treatment of Human Cancers","toc_doc":"Development of an Anti-GPC3 Chimeric Antigen Receptor Based on HN3 for the Treatment of Human Cancers","toc_subject":"Exclusive Licenses:","topics":[],"type":"Notice","volume":81}